研究单位：[1]Tasly Biopharmaceuticals Co., Ltd.[2]Fuwai Hospital,Beijing,China,100037[3]Anzhen Hospital, Capital Medical University,Beijing,China[4]Beijing Tongren Hospital,Capital Medical University,Beijing,China[5]The Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China[6]Henan Provincial People's Hospital,Zhengzhou,Henan,China[7]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[8]Wuhan Asia Heart Hospital,Wuhan,Hubei,China[9]Xiangya Hospital, Central South University,Changsha,Hunan,China[10]Jiangsu Province Hospital,Nanjing,Jiangsu,China[11]Nanjing First Hospital,Nanjing,Jiangsu,China[12]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[13]The First Hospital of Jilin University,Changchun,Jilin,China[14]The First Hospital of China Medical University,Shenyang,Liaoning,China[15]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China[16]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China[17]West China Hospital of Sichuan University,Chengdu,Sichuan,China[18]Tianjin Chest Hospital,Tianjin,China[19]Sir Run Run Shaw Hospital affiliated with the Zhejiang University School of Medicine,Hangzhou,Zhejiang,China
研究目的：
This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.
